



October 18, 2018

FIELD SAFETY CORRECTIVE ACTION NOTIFICATION

iChem VELOCITY Urine Chemistry Strips

PN 800-7212 and 800-7204

Attention Beckman Coulter Customer,

Copy: Chairman Medical Board/Head of Departments of Affected consignees

**Applicable to Affected consignees of Singapore only*

Beckman Coulter is initiating a field safety corrective action for the products listed above. This letter contains important information that needs your immediate attention.

<p>ISSUE:</p>	<p>Beckman Coulter has become aware of an increase in the sensitivity of the urobilinogen reaction via customer reports of falsely elevated (false positive) urobilinogen patient results for iChemVELOCITY Urine Chemistry strips. Affected strips are detailed in the table below:</p> <table border="1" data-bbox="397 987 1510 1249"> <thead> <tr> <th data-bbox="397 987 527 1024">REF</th> <th data-bbox="527 987 1510 1024">Affected Lots (manufactured since July 2017)</th> </tr> </thead> <tbody> <tr> <td data-bbox="397 1024 527 1123">800-7212</td> <td data-bbox="527 1024 1510 1123">Lot numbers beginning with lot 7212143 except for: 7212146, 7212148, 7212160, 7212162, 7212163 and 7212164.</td> </tr> <tr> <td data-bbox="397 1123 527 1249">800-7204</td> <td data-bbox="527 1123 1510 1249">Lot numbers beginning with lot 7204166 except for: 7204167, 7204168, 7204169, 7204170, 7204171, 7204172, 7204184, 7204185, 7204186 and 7204187.</td> </tr> </tbody> </table>	REF	Affected Lots (manufactured since July 2017)	800-7212	Lot numbers beginning with lot 7212143 except for: 7212146, 7212148, 7212160, 7212162, 7212163 and 7212164.	800-7204	Lot numbers beginning with lot 7204166 except for: 7204167, 7204168, 7204169, 7204170, 7204171, 7204172, 7204184, 7204185, 7204186 and 7204187.
REF	Affected Lots (manufactured since July 2017)						
800-7212	Lot numbers beginning with lot 7212143 except for: 7212146, 7212148, 7212160, 7212162, 7212163 and 7212164.						
800-7204	Lot numbers beginning with lot 7204166 except for: 7204167, 7204168, 7204169, 7204170, 7204171, 7204172, 7204184, 7204185, 7204186 and 7204187.						
<p>IMPACT:</p>	<ul style="list-style-type: none"> • There is the potential for erroneous falsely elevated/false positive urobilinogen results reported to the physician. Patient results at the high end of the normal range for urobilinogen may be reported as abnormal (the first positive range) indicating an erroneous above normal result. <ul style="list-style-type: none"> ○ For 800-7212: This affects the 2 mg/dL reportable range (first abnormal range) ○ For 800-7204: This affects the 2 mg/dL and 3 mg/dL reportable range (first abnormal range) • As the worst case scenario, erroneous results released out of the lab may lead to additional minimally invasive work-up, including venipuncture resulting in temporary injury to the patient. • This issue is not detected by quality control. • There is no impact to the results of other analytes on the strip. 						
<p>ACTION:</p>	<ul style="list-style-type: none"> • Review abnormal urobilinogen results to determine if they are consistent with the patient's other clinical findings and result parameters. 						

	<ul style="list-style-type: none"> • As an option, perform urobilinogen testing using an alternative, backup method, if needed, per your laboratory protocol. <ul style="list-style-type: none"> ◦ Note: Strips reporting in units of “Ehrlich units/dL” may give different results from strips reporting in units of mg/dL. • If using instrument’s auto-release feature, consider establishing a chemistry confirmation threshold for urobilinogen. Refer to your instrument’s Instruction for Use (IFU) Chapter 9 “Setup”. Consult your local Beckman Coulter representative for guidance, if needed. • Consult with your Laboratory Director to determine if a retrospective review of results is clinically warranted.
RESOLUTION:	Beckman Coulter is actively working on a resolution to prevent the recurrence of this issue.

The national competent authority has been informed of this field safety corrective action.

Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded any of the affected product(s) listed above to another laboratory, please provide them with a copy of this letter.


Please complete and return the enclosed Response Form within 10 days so we are assured you have received this important communication.

If you have any questions regarding this notice, please contact our Customer Support Center:

- From our website, <http://www.beckmancoulter.com/customersupport/support>

We apologize for the inconvenience that this caused to your laboratory.

Sincerely,



Roger A Janczak
Vice President, Quality Assurance and Regulatory Affairs

Enclosure: Response Form